The effect of HI-TOPK-032 on the proliferation of ovarian cancer based on a nude mouse model

doi:10.3969/j.issn.1006-7795.2024.04.008

Abstract

Abstract: Objective To investigate the expression of T-LAK cell-originated protein kinase/PDZ-binding-kinase (TOPK/PBK) in ovarian cancer and the effect of HI-TOPK-032, an inhibitor of TOPK/PBK, on ovarian cancer cells. Methods The expression of TOPK/PBK in ovarian cancer tissue and normal samples were analyzed by gene expression profiling interactive analysis (GEPIA) software. The effect of HI-TOPK-032 on the proliferative activity of ovarian cancer cells was analyzed by methyl thiazolyl tetrazolium (MTT) assay and colony formation assay. The effect of HI-TOPK-032 was also assessed on subcutaneous ovarian tumor in nude mice. Results The expression of TOPK/PBK in ovarian cancer was significantly higher than that in normal ovarian tissue (P<0.05). With the treatment of HI-TOPK-032, the expression of TOPK/PBK was inhibited, and the proliferation capacity of OVCAR3 and SKOV3 cells decreased (P<0.0001). The mass ［(1.514±0.358)g vs (0.670±0.450)g］ and volume ［(0.418±0.171)cm3 vs (0.973±0.262)cm3］ of subcutaneous tumors in the HI-TOPK-032 treatment group were significantly lower than that in the control group. Conclusions TOPK/PBK is highly expressed in ovarian cancer, contributing to the growth of ovarian cancer. HI-TOPK-032 exerts an inhibiting effect on the growth of ovarian cancer.

Key words: ovarian cancer, HI-TOPK-032, T-LAK cell-originated protein kinase/PDZ-binding-kinase, cell proliferation

CLC Number:

R737.31

Tang Fan, Deng Mengqi, Miao Jinwei. The effect of HI-TOPK-032 on the proliferation of ovarian cancer based on a nude mouse model[J]. Journal of Capital Medical University, 2024, 45(4): 609-615.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2024.04.008

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2024/V45/I4/609

References

［1］ Webb P M, Jordan S J. Global epidemiology of epithelial ovarian cancer［J］. Nat Rev Clin Oncol, 2024, 21(5): 389-400.
［2］ Zhang L, Wang F, Yi H J, et al. The role of T-LAK cell-originated protein kinase in targeted cancer therapy［J］. Mol Cell Biochem, 2022, 477(3): 759-769.
［3］ Kim D J, Li Y, Reddy K, et al. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth［J］. Cancer Res, 2012, 72(12): 3060-3068.
［4］ Ikeda Y, Park J H, Miyamoto T, et al. T-LAK cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in ovarian cancer［J］. Clin Cancer Res, 2016, 22(24): 6110-6117.
［5］ Zhao R, Choi B Y, Wei L X, et al. Acetylshikonin suppressed growth of colorectal tumour tissue and cells by inhibiting the intracellular kinase, T-lymphokine-activated killer cell-originated protein kinase［J］. Br J Pharmacol, 2020, 177(10): 2303-2319.
［6］ Peng S F, Yin Y H, Zhang Y Z, et al. FYN/TOPK/HSPB1 axis facilitates the proliferation and metastasis of gastric cancer［J］. J Exp Clin Cancer Res, 2023, 42(1): 80.
［7］ Thanindratarn P, Wei R, Dean D C, et al. T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma［J］. Mol Oncol, 2021, 15(12): 3721-3737.
［8］ Li J X, Sun H M, Fu M L, et al. TOPK mediates immune evasion of renal cell carcinoma via upregulating the expression of PD-L1［J］. iScience, 2023, 26(7): 107185.
［9］ Ma H L, Li Y W, Wang X X, et al. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma［J］. Cell Death Dis, 2019, 10(3): 166.
［10］ Ma H L, Qi G H, Han F, et al. PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer［J］. Exp Mol Med, 2022, 54(7): 999-1010.
［11］ Wu W J, Xu J L, Gao D, et al. TOPK promotes the growth of esophageal cancer in vitro and in vivo by enhancing YB1/eEF1A1 signal pathway［J］. Cell Death Dis, 2023, 14(6): 364.
［12］ Xiao J J, Zhang L, Yi H J, et al. Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC［J］. Cell Death Dis, 2022, 13(9): 828.
［13］ Zhang Q F, Zheng F, Chen Y C, et al. The TOPK inhibitor HI-TOPK-032 enhances CAR t-cell therapy of hepatocellular carcinoma by upregulating memory T cells［J］. Cancer Immunol Res, 2024, 12(5): 631-643.
［14］ Sun G Z, Ye N, Dai D X, et al. The protective role of the TOPK/PBK pathway in myocardial ischemia/reperfusion and H2O2-induced injury in H9C2 cardiomyocytes［J］. Int J Mol Sci, 2016, 17(3): 267.
［15］ Gao S M, Zhu Y, Li H B, et al. Remote ischemic postconditioning protects against renal ischemia/reperfusion injury by activation of T-LAK-cell-originated protein kinase (TOPK)/PTEN/Akt signaling pathway mediated anti-oxidation and anti-inflammation［J］. Int Immunopharmacol, 2016, 38: 395-401.

[1]	Wang Wenwen, Cai Yu, Jia Shuangshuang, Zhai Jianjun. Relationship between kinesin family proteins 2C and chemoresistance in ovarian cancer [J]. Journal of Capital Medical University, 2023, 44(1): 143-147.
[2]	Liu Qun, Li Lina, Liu Jian, Miao Jinwei. SOX4 mediates TGF-β1 induced epithelial-mesenchymal transition to promote invasion and metastasis of ovarian cancer [J]. Journal of Capital Medical University, 2022, 43(3): 336-342.
[3]	Tian Ming, Kong Qiu, Hou Xiaoxiao, Miao Jinwei. Clinicopathological analysis of benign and malignant struma ovarii [J]. Journal of Capital Medical University, 2022, 43(3): 343-349.
[4]	Zhang Zixin, Meng Ying, Liang Yuting. MR-NIRF Fe₃O₄-Cy5.5-NGR bimodel contrast agents ovarian cancer cells [J]. Journal of Capital Medical University, 2018, 39(1): 84-91.
[5]	Wei Wei;Shen Keng;Zhao Lihong;Cao Yang. Establishment of Fisher344 Rat Animal Model of Epithelial Ovarian Cancer [J]. Journal of Capital Medical University, 2007, 28(1): 52-55.
[6]	Duan Aihong;Zhang Jianping;Lu Dan. Histopathologic Category and Treatment of Parovarian Cyst [J]. Journal of Capital Medical University, 2006, 27(5): 681-683.
[7]	Chen Shengping;Wang Xiangping;Zhou Lianer. Serus Matrix Metalloproteinases(MMP-2, MMP-9) and Ovarian Epithelial Tumor [J]. Journal of Capital Medical University, 2006, 27(4): 533-535.
[8]	Tang Lirong;Duan Wei;Fan Fengxiao;Xu Xiaohong . Histological Classification in 3582 Cases of Ovarian Tumors [J]. Journal of Capital Medical University, 2004, 25(1): 110-113.